KRAS and pancreatic neoplasm: Partial responses occurred in 3 of 78 patients (importantly, all 3 had KRAS or BRAF mutations) and stable disease for more than 5 months was seen in 5 patients.36 Another phase 1 trial (NCT01392521) involving MEK (refametinib) and PI3K (copanlisib) inhibitors, refametinib in advanced solid cancers demonstrated a single patient with partial response and 9 with stable disease out of 49 enrolled patients.37 A phase 1 study of MEK (trametinib) and PI3K (buparlisib) inhibitors was conducted in 113 patients with RAS or RAF mutant non‐small cell lung, ovarian, and pancreatic cancers.